Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Surgical management of oligometastatic recurrence in primary esophageal melanoma: a feasible approach in resource-limited settings.
J Surg Case Rep
March 2025
Pathology Department, NPO "National Cancer Institute", 33/43 Yulii Zdanovskoi street, Holosiivskyi District, Kyiv 03022, Ukraine.
Primary esophageal melanoma (PEM) is a rare and aggressive malignancy with limited treatment options. Due to its rarity, no standardized guidelines exist for managing oligometastatic recurrence, particularly in resource-limited settings. We present a case of a 60-year-old male with PEM who underwent esophagectomy followed by surgical resection of an adrenal metastasis.
View Article and Find Full Text PDFSkin cancer is the most commonly diagnosed malignancy in the United States, costing more than $8.1 billion annually in treatment-related expenses, yet with ultraviolet exposure considered the most significant risk factor for skin cancer development, cutaneous malignancy is also highly preventable. The Affordable Care Act (ACA) is committed to covering demonstrably effective preventive health care measures without patient cost sharing.
View Article and Find Full Text PDFReal-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF-mutant melanoma in Spain: the BECARE (GEM-2002) trial.
Front Oncol
February 2025
Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Ciudad de Murcia, Spain.
Purpose: Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B) has demonstrated efficacy and tolerability in phase III clinical trials, and is the standard of care for advanced/metastatic BRAF-mutant melanoma. However, real-life evidence is limited, particularly in patients pre-treated with immune checkpoint inhibitors (ICI).
Patients And Methods: BECARE GEM 2002 was a retrospective, non-interventional study aimed at investigating the real-world effectiveness and tolerability of EB in patients with unresectable or metastatic BRAF-mutant melanoma conducted at 21 sites in Spain.
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico.
J Med Econ
December 2025
Adelphi Values PROVE, Bollington, UK.
Introduction: Melanoma, responsible for most skin cancer deaths globally, has mortality rates expected to double by 2040. Pembrolizumab is a highly selective antibody approved for melanoma treatment and other cancers. Despite new treatments for melanoma, high treatment costs and long approval times limit patient access to new therapies.
View Article and Find Full Text PDFSmartphone-Manipulated Mild-Temperature Photothermal Control of the TfR-LYTAC Platform for Tumor Treatment.
Nano Lett
March 2025
College of Food Science and Technology, Yunnan Agricultural University, No. 452 Fengyuan Road, Kunming 650201, China.
A lysosome-targeting chimera (LYTAC) offers a novel strategy for degrading extracellular proteins previously considered to be undruggable by hijacking the lysosomal degradation system. However, clinical use of LYTAC has been limited due to the potential for uncontrolled degradation and systemic toxicity. Based on our previously developed genetically encoded TfR-LYTAC, here, we introduce a photothermal-inducible switch in the engineered bacterium to enable spatiotemporal expression of TfR-LYTAC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!